Ottawa, Feb. 04, 2026 (GLOBE NEWSWIRE) -- The global diabetic neuropathy treatment market size is calculated at USD 5.47 billion in 2026 and is expected to reach around USD 9.93 billion by 2034, growing at a CAGR of 7.75% for the forecasted period. The …

Huntington's disease causes progressive breakdown of nerve cells in the brain. Photo: 123RF A treatment for Huntington's disease being trialled in New Zealand and Australia is showing promising early results, the US biotech company behind the drug …

By Steven Scheer JERUSALEM, Jan 28 (Reuters) - Teva Pharmaceutical Industries reported strong quarterly results on Wednesday but forecast lower net profit and revenue in 2026 on a more ​than $1 billion expected loss in sales of its generic version of a …

Ottawa, Jan. 22, 2026 (GLOBE NEWSWIRE) -- The global clinical trials market size is calculated at USD 93.15 billion in 2025, grew to USD 99.21 billion in 2026, and is projected to reach around USD 175.02 billion by 2035. The market is projected to expand …

NEW YORK, TEL AVIV, Israel & AARHUS, Denmark--(BUSINESS WIRE)--Jan 21, 2026-- NeuraLight, the leader in developing precision brain function measures, and Teitur Trophics ApS, a pioneering biotech company developing first-in-class therapeutics for …

uniQure N.V. (NASDAQ:QURE) shares are popping on Friday after the company said the FDA will review the data package for AMT‑130, its gene therapy for Huntington's disease, with a Type A meeting now scheduled. uniQure shares are powering higher. Why is …

It is investigating small molecule drugs that could stop the pathogenic triplet expansion that is the cause and driver of HD, myotonic dystrophy type 1, and other triplet repeat expansion diseases. It posits that DNA mismatch repair has been shown as a key …

NESS ZIONA, Israel, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, will participate in the 44th …

FDA Law-Not Hemp, Marijuana Politics-Will Decide the Future of Cannabinoid Medicine. Why "Full-Spectrum CBD" Narratives Are Collapsing-and Why MMJ International Holdings DRUG Development Strategy Was Right All Along" stated Duane Boise, CEO …

ALBANY - Instead of finding treatments for one rare disease, two University at Albany researchers have developed a compound that could provide relief for sufferers of dozens of degenerative neurological illnesses. The pair just won $50,000 in State …